معرفی
Chudan Xu is a Research Fellow in Pharmacology at Monash University, specializing in the gut microbiome's role in hypertension and cardiovascular diseases. Her work bridges microbiology, pharmacology, and nutritional science to explore dietary interventions for blood pressure regulation.
She earned her PhD in Biomedical Science from Monash University in October 2024 with a dissertation on Novel Gut Microbial Metabolites in Hypertension.
Dr. Xu's research focuses on hypertension mechanisms involving gut microbiome-derived metabolites, dietary fiber interventions, and blood pressure regulation. Key themes include microbial metabolite signaling, end-organ damage pathways, and pH-sensor biology (e.g., GPR68), with direct implications for cardiovascular therapeutics.
Analysis of her 2022-2025 publications reveals a cohesive trajectory: establishing dietary fiber-microbiome-blood pressure connections (2022), challenging paradigms on microbiota and end-organ damage (2023), and identifying molecular mediators like GPR68 (2025). Her work integrates cardiovascular physiology, microbiome ecology, and translational pharmacology.
Her awards include:
- Paul Dudley White International Scholar Award (August 2020)
- Hypertension Early Career Oral Presentation Award (September 2020)
- HBPRCA Student Oral Finalist (December 2020)
- HBPRCA Student Poster Finalist (December 2022)
- SCIEX Early Career Researchers Competition (December 2020)
Dr. Xu maintains active collaborations with Prof. Francine Z. Marques' lab and international networks, evidenced by co-authorship on high-impact reviews. Her research has reached 8 news outlets, 50+ X users, and 300+ Mendeley readers, reflecting significant scientific and public impact. She contributes to UN Sustainable Development Goal 3 (Good Health and Well-being) through hypertension research.
